JPRN-UMIN000033796招募中2 期
Phase 2 study of S-IROX as down staging chemotherapy for borderline resectable pancreatic cancer - BR-SIROX
Department of Hepatobiliary and Pancreatic Oncology/Surgery National Canser Center0 个研究点目标入组 24 人开始时间: 2018年8月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •History of treatment of other cancer
研究者
相似试验
招募中
2 期
BR-SIROXPancreatic cancerJPRN-jRCTs031180263Esaki Minoru24
已完成
不适用
Phase I/II study of S-IROX as second-line therapy after nab-Paclitaxel + Gemcitabine for unresectable pancreatic cancerThe unresectable advanced pancreatic cancer after first-line Nab-Paclitaxel+Gemcitabine failureJPRN-UMIN000036969Gifu Municipal Hospital25
已完成
不适用
A phase I/II study of chemotherapy using S-1, Oxaliplatin plus Irinotecan for unresectable pancreatic cancerunresectable pancreatic cancerJPRN-UMIN000014471Department of Gastroenterology Kitasato University School of Medicine25
已完成
2 期
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.Gastrointestinal NeoplasmGastric AdenocarcinomaNCT01129310AHS Cancer Control Alberta47
已完成
2 期
A phase II study of first line chemotherapy by eribulin mesilate for HER2 negative recurrent breast cancerBreast cancerJPRN-UMIN000007990Kobe Breast Cancer Oncology Group35